$2.17
4.83%
Nasdaq, Oct 28, 04:00 pm EDT. Closed.
ISIN
US31189P1021
Symbol
FATE

Fate Therapeutics, Inc. Stock price

$2.17
-0.21 8.82% 1M
+0.87 66.92% 6M
+1.19 120.84% YTD
+0.68 45.64% 1Y
+0.44 25.43% 3Y
-53.81 96.12% 5Y
-0.01 0.46% 10Y
-4.45 67.22% 20Y
Nasdaq, Closing price Wed, Oct 28 2026
+0.10 4.83%
ISIN
US31189P1021
Symbol
FATE
Industry

Is Fate Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,100 stocks worldwide.

Key metrics

Basic
Market capitalization
$260.0m
Enterprise Value
$118.1m
Net debt
positive
Cash
$153.8m
Shares outstanding
116.7m
Valuation
P/E
negative
P/S | estimate
40.1 | 45.3
EV/Sales | estimate
18.2 | 20.6
EV/FCF | ex SBC
negative | negative
P/B
1.7
Financial Health
Equity Ratio
65.0%
Return on Equity
-65.8%
ROCE
-58.7%
ROIC
-
Debt/Equity
0.1
Share-Based Compensation & Dilution
SBC | % of Revenue
$17.8m | 274.9%
SBC as % of FCF
-
SBC Growth 1Y
-49.6%
Share Count Growth 1Y
1.8%
Shareholder Yield
-1.8%
Financials
Revenue | estimate
$6.5m | $5.7m
EBITDA
$-121.6m
EBIT
$-133.6m
Net Income
$-126.0m
Free Cash Flow | ex SBC
$-105.7m | $-123.5m
Growth
Revenue | estimate
-23.4% | -13.8%
EBITDA
31.0%
EBIT
30.6%
Net Income
26.5%
Free Cash Flow
11.0%
Margin
Gross
-
EBITDA
-1,873.4%
EBIT
-2,058.1%
Net
-1,941.1%
Free Cash Flow | ex SBC
-1,627.8% | -1,902.5%
More
EPS
$-1.1
FCF per Share
$-0.9
Short interest
10.1%
Employees
161
Rev per Employee
$40.0k

Fate Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Fate Therapeutics, Inc. forecast:

11x Buy
61%
7x Hold
39%

Analyst Opinions

18 Analysts have issued a Fate Therapeutics, Inc. forecast:

Buy
61%
Hold
39%

Fate Therapeutics, Inc. Events

Upcoming Event
OCT
29
Q3 2026 Earnings Call
TODAY
View Past Earnings Reaction

Financial data from Fate Therapeutics, Inc.

Jun '26
+/-
%
6.49 6.49
23% 23%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
35% 35%
612%
- Research and Development Expense 100 100
20% 20%
1,546%
-122 -122
31% 31%
-1,874%
- Depreciation and Amortization 12 12
25% 25%
185%
EBIT (Operating Income) EBIT -134 -134
31% 31%
-2,058%
Net Profit -126 -126
27% 27%
-1,941%

In millions USD.

Don't miss a Thing! We will send you all news about Fate Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fate Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
●
3 days ago
Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with approximately 50% mean reduction in proteinuria Encouraging safety profile with no dose-limiting toxicities, high-grade CRS, ICANS, GvHD or IEC-HS in autoimmune patients treated with a single dose of...
Neutral
GlobeNewsWire
●
27 days ago
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2026, the Company granted (i) non-qualified stock options to one...
Neutral
GlobeNewsWire
●
28 days ago
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the fourt...
More Fate Therapeutics, Inc. News

Company Profile

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Dr. Valamehr
Employees 161
Founded 2007
Website fatetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today